Theravance Biopharma, Inc. Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
Theravance Biopharma, Inc. (TBPH) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of $1.12 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-27.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2020-02-27
- Theravance Biopharma, Inc. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-12-31 was $0.00.
- Theravance Biopharma, Inc. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-09-30 was $0.00.
- Theravance Biopharma, Inc. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-06-30 was $0.00.
- Theravance Biopharma, Inc. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-03-31 was $1.12M.
- Theravance Biopharma, Inc. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2018 was $1.12M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 6 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 9 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $1.12M 10-K · filed 2020-02-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $1.12M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $1.12M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $1.12M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |